Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TECH | 8-K | bullish | 7/10 | Bio-Techne reported Q4 FY2026 results with organic revenue growth of 3% (reported +1% to $321.2M), GAAP EPS of $0.35 vs | Aug 12, 2026 |
| LQDA | 8-K | bullish | 6/10 | Liquidia reported Q2 2026 net product sales of $170.4M (+31% QoQ), net income of $74.7M ($0.74 diluted EPS), and adjuste | Aug 12, 2026 |
| DNTH | CLUSTER | neutral | 3/10 | A cluster of insider selling at Dianthus Therapeutics (DNTH) totaling $2.99M over a 7-day window, led by the CEO ($1.12M | Aug 12, 2026 |
| LLY | CLUSTER | neutral | 3/10 | Two senior Eli Lilly executives (SVP Finance/CAO and EVP GC/Secretary) sold a combined $8.32M in open-market sales over | Aug 12, 2026 |
| TWST | CLUSTER | neutral | 4/10 | A cluster of insider sales at Twist Bioscience totaling $4.39M occurred within 9 days of a strong Q3 2026 earnings beat | Aug 12, 2026 |
| CRL | CLUSTER | neutral | 3/10 | A cluster of insider selling at Charles River Laboratories (CRL) totaling $10.5M in open-market sales occurred within 7 | Aug 12, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | CEO Martine Rothblatt sold ~$5.5M in open-market shares on August 10, 2026, following option exercises, while EVP Paul M | Aug 12, 2026 |
| SLXN | PRESS-RELEASE | bearish | 7/10 | Silexion Therapeutics priced a public offering of 3,846,161 ordinary shares (or equivalents) and series E warrants at $0 | Aug 11, 2026 |
| MLTX | INST-CLUSTER | bullish | 5/10 | Six institutional buyers accumulated $1.4M in MLTX during Q2 2026, led by State Street (+$644K) and Nuveen (+$328K), whi | Aug 11, 2026 |
| AXSM | INST-CLUSTER | mixed | 5/10 | Q2 2026 13F cluster for Axsome Therapeutics shows a mixed institutional picture: 9 smaller buyers added $24.4M in new po | Aug 11, 2026 |
| ABSI | INST-CLUSTER | bullish | 5/10 | A strong institutional cluster emerged in Absci Corp during 2026-Q2, with 10 funds all accumulating positions totaling $ | Aug 11, 2026 |
| ACRS | INST-CLUSTER | bullish | 5/10 | A strong institutional accumulation cluster in Aclaris Therapeutics during Q2 2026, with 10 buyers adding $43.5M in net | Aug 11, 2026 |
| TNGX | 8-K | bearish | 6/10 | Tango Therapeutics upsized its at-the-market (ATM) equity offering program from $100M to $400M, terminating the prior $1 | Aug 11, 2026 |
| ARQT | 144 | neutral | 3/10 | Patrick Burnett, an officer of Arcutis Biotherapeutics, filed a Form 144 on August 11, 2026, indicating intent to sell 1 | Aug 11, 2026 |
| DNTH | CLUSTER | neutral | 3/10 | Three Dianthus Therapeutics insiders (CEO, General Counsel, and a Director) sold a total of ~$3.2M in open-market shares | Aug 11, 2026 |
| MIRM | CLUSTER | bearish | 5/10 | CEO Christopher Peetz executed a cluster of open-market sales totaling ~$1.98M, including a single-day sale of 11,683 sh | Aug 11, 2026 |
| EPRX | PRESS-RELEASE | neutral | 4/10 | Eupraxia Pharmaceuticals reported Q2 2026 financial results with a net loss of $14.5M, up from $8.7M a year ago, driven | Aug 11, 2026 |
| DNTH | CLUSTER | bearish | 6/10 | CEO Marino Garcia and General Counsel Adam Veness executed a cluster of open-market sales totaling ~$20.0M over two days | Aug 11, 2026 |
| ACHV | 8-K | neutral | 5/10 | Achieve Life Sciences reported Q2 2026 financial results, highlighting a net loss of $74.8M for the quarter (including a | Aug 11, 2026 |
| VVOS | 8-K | bullish | 5/10 | Vivos Therapeutics announced the issuance of US Patent No. 12,697,190, a continuation patent that broadens protection fo | Aug 11, 2026 |
| BBOT | PRESS-RELEASE | neutral | 2/10 | BridgeBio Oncology Therapeutics (BBOT) awarded inducement stock grants to two new employees under its 2025 Inducement Pl | Aug 11, 2026 |
| IMNN | 8-K | neutral | 3/10 | Imunon filed an 8-K disclosing that its Compensation Committee approved stock-for-salary election programs for three top | Aug 11, 2026 |
| AVXL | 8-K | neutral | 4/10 | Anavex filed definitive proxy materials for its September 24, 2026 annual meeting, urging shareholders to vote for its s | Aug 11, 2026 |
| AARD | 8-K | bearish | 8/10 | Aardvark Therapeutics reported Q2 2026 financial results with a net loss of $14.4M (EPS -$0.66), essentially flat vs the | Aug 11, 2026 |
| CRDF | PRESS-RELEASE | bearish | 6/10 | Cardiff Oncology reported Q2 2026 EPS of -$0.18, missing consensus of -$0.16 by 12.5%, with revenue of $104K (below $63K | Aug 11, 2026 |
| LENZ | PRESS-RELEASE | mixed | 5/10 | LENZ Therapeutics reported Q2 2026 revenue of $5.5M (beating $2.4M consensus) and EPS of -$1.02 (beating -$1.07 consensu | Aug 11, 2026 |
| AARD | PRESS-RELEASE | bearish | 6/10 | Aardvark Therapeutics reported Q2 2026 net loss of $14.4M ($0.66 per share), in line with the prior year, while cash bur | Aug 11, 2026 |
| ABCL | 424B5 | bearish | 7/10 | AbCellera Biologics Inc. filed a preliminary prospectus supplement for a $200 million underwritten public offering of co | Aug 11, 2026 |
| KYTX | 8-K | bullish | 6/10 | Kyverna reported Q2 2026 net loss of $0.63 per share, narrower than the $0.67 consensus, with cash burn continuing. The | Aug 11, 2026 |
| ENGN | 8-K | neutral | 3/10 | enGene Therapeutics hosted a virtual KOL event on August 11, 2026, presenting market research on the NMIBC BCG-unrespons | Aug 11, 2026 |